initial public offerings (IPOs) trading on American exchanges
Showing posts with label ARGX. Show all posts
Showing posts with label ARGX. Show all posts

Wednesday, November 20, 2024

Forte Biosciences (FBRX) : 7-year performance

Note: Forte Biosciences was acquired by the global immunology company argenx SE (ARGX) in a cash tender offer and merger valued at approximately $2.2 billion ($77.00 per share).  (August 2026)

 



Friday, June 21, 2024

argenx (ARGX) : FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy

argenx Announces FDA Approval of VYVGART Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy 
  • VYVGART Hytrulo is first and only neonatal Fc receptor (FcRn) blocker approved to treat chronic inflammatory demyelinating polyneuropathy (CIDP)
IPO: 18 May 2017
Ticker: ARGX




argenx SE, a commercial-stage biopharma company, develops various therapies for the treatment of autoimmune diseases. The company offers VYVGART for the treatment of gMG and immune thrombocytopenia (ITP), and VYVGART HYTRULO for the treatment of gMG and chronic inflammatory demyelinating polyneuropathy (CIDP). It also develops efgartigimod for the treatment of seronegative gMG, ocular myasthenia gravis (MG), primary ITP, grave's disease, myositis, Sjögren's disease, systemic sclerosis, and AMR; empasiprubart for MMN, delayed graft function, and CIDP; and adimanebart for congenital myasthenic syndrome and spinal muscular atrophy.
  • Sector: Healthcare
  • Industry: Biotechnology
  • Full Time Employees: 1,863
  • Incorporated in 2008 
  • HQ in Amsterdam, the Netherlands
  • https://argenx.com


June 21, 2024, 4:40pm ET

Amsterdam, the Netherlands – argenx SE (Euronext & Nasdaq: ARGX), a global immunology company committed to improving the lives of people suffering from severe autoimmune diseases, today announced that the U.S. Food and Drug Administration (FDA) has approved VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc) for the treatment of adult patients with chronic inflammatory demyelinating polyneuropathy (CIDP). VYVGART Hytrulo is approved for CIDP as a once weekly 30-to-90 second subcutaneous injection. It is the first and only neonatal Fc receptor (FcRn) blocker approved for the treatment of CIDP.

“argenx continues to pursue our ambition to turn science into solutions for patients with severe autoimmunity,” said Luc Truyen M.D., Ph.D., Chief Medical Officer, argenx. “Patients have been waiting, and today argenx is delivering the first innovative treatment for CIDP in more than 30 years. VYVGART Hytrulo is a precision tool that has been shown to drive meaningful benefits for patients. Today’s FDA approval means that CIDP patients have a transformational new treatment option and further affirms the therapeutic profile of VYVGART Hytrulo and the potential of FcRn blockade in IgG-mediated autoimmune diseases.”

CIDP is a rare, debilitating, often progressive, immune-mediated neuromuscular disorder of the peripheral nervous system. Patients experience a range of disabling mobility and sensory issues, including trouble standing from a seated position, pain and fatigue, and frequent tripping or falling. Many patients become wheelchair bound and are unable to work as the disease progresses. Currently, 85% of patients require ongoing treatment and nearly 88% of treated patients experience residual impairment and disability.
 

Tuesday, June 16, 2020

Tocagen (TOCA) and Forte Biosciences merge; trade as Forte Biosciences (FBRX)

Note: Forte Biosciences was acquired by the global immunology company argenx SE (ARGX) in a cash tender offer and merger valued at approximately $2.2 billion ($77.00 per share).  (August 2026)
***
Tocagen Inc. (Nasdaq: TOCA), and Forte Biosciences, Inc., a privately held clinical-stage biopharmaceutical company developing a live biotherapeutic for the treatment of inflammatory skin diseases, announced today that they have entered into a definitive agreement under which Tocagen will merge with Forte in an all-stock transaction.

The merged company will focus on advancing Forte's clinical program in inflammatory skin diseases, including atopic dermatitis. The combined company operates under the name Forte Biosciences and trades on the Nasdaq Capital Market under the ticker symbol FBRX.

Paul Wagner, CEO

***
Tocagen was a struggling brain cancer biotech whose huge Phase III failure triggered mass layoffs at the company.

Forte Biosciences is a biotech tackling atopic dermatitis and other inflammatory skin diseases.

Three years years ago, Tocagen went public and raised $85 million on the promise of a two-part therapy for glioblastoma. Part 1 used a vector to attack cancer cells and deliver the gene for an enzyme and Part 2 was a prodrug that converts into an anti-cancer drug. It was an intriguing approach to a deadly indication that has evaded most previous attempts, but in September, in its biggest test, the two-part therapy showed all but no signs of working.

In fact, patients on the control arm lived a month longer on average than patients on the drug arm, 12.2 vs 11.1. That computed to a hazard ratio of 1.06 and a p-value of 0.62. The company’s stock dropped 81% on the announcement, and a month later they cut 65% of their workforce, leaving the San Diego-based biotech with just 30 employees.